Integer (NYSE:ITGR) Issues FY24 Earnings Guidance

Integer (NYSE:ITGR) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $5.01-5.43 for the period, compared to the consensus EPS estimate of $5.31. The company issued revenue guidance of 1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion.

Integer Stock Performance

Shares of NYSE:ITGR opened at $123.34 on Thursday. The stock has a market capitalization of $4.13 billion, a P/E ratio of 45.85, a P/E/G ratio of 1.63 and a beta of 1.10. Integer has a 1-year low of $69.40 and a 1-year high of $123.99. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $112.68 and a two-hundred day moving average price of $99.49.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.05. The firm had revenue of $413.15 million during the quarter, compared to analysts’ expectations of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.11 EPS. Equities analysts predict that Integer will post 5.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ITGR. Benchmark upped their price target on Integer from $105.00 to $130.00 and gave the company a buy rating in a research note on Thursday, March 28th. Bank of America raised Integer from a neutral rating to a buy rating and increased their target price for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. KeyCorp increased their target price on Integer from $123.00 to $139.00 and gave the stock an overweight rating in a research note on Tuesday, April 9th. Finally, CL King initiated coverage on Integer in a research note on Thursday, March 14th. They set a buy rating and a $137.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.